Results 31 to 40 of about 26,025 (223)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation

Haematologica, 2022
BCL-2 family proteins are frequently aberrantly expressed in mantle cell lymphoma (MCL). Recently, the BCL-2-specific inhibitor venetoclax has been approved by the US Food and Drug Administration for chronic lymphocytic leukemia (CLL) and acute myeloid ...
Yvonne J. Thus, Martin F.M. de Rooij, Nathalie Swier, Roderick L. Beijersbergen, Jeroen E.J. Guikema, Marie-José Kersten, Eric Eldering, Steven T. Pals, Arnon P. Kater, Marcel Spaargaren   +9 more
doaj   +1 more source

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. [PDF]

, 2019
Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer histotype, characterized by high biological aggressiveness and scarce treatment options.
Calvisi, Diego F, Che, Li, Chen, Xin, Evert, Matthias, Hu, Junjie, Liu, Xianqiong, Lu, Xinjun, Song, Xinhua, Su, Tao, Utpatel, Kirsten, Wang, Jingxiao, Wang, Pan, Xu, Meng, Zhang, Jie, Zhang, Yi   +14 more
core   +1 more source

Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals [PDF]

, 2016
Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome, but many patients relapsed or become refractory to the available treatments.
Facco, Monica, Frezzato, Federica, Martini, Veronica, Semenzato, Gianpietro, Severin, Filippo, Trentin, Livio, Trimarco, Valentina, Visentin, Andrea   +7 more
core   +1 more source

Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review

Hematology, Transfusion and Cell Therapy
Background: Based on the VIALE-A and VIALE-C studies, the Food and Drug Administration approved venetoclax in 2020 in combination with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia ineligible for intensive ...
Lauro Fabián Amador-Medina, Erick Crespo-Solís, Francisco Javier Turrubiates-Hernández, Karla Edith Santibañez-Bedolla   +3 more
doaj   +1 more source

Clinical Pharmacology & Therapeutics: Past, Present, and Future. [PDF]

, 2017
Clinical Pharmacology & Therapeutics (CPT), the definitive and timely source for advances in human therapeutics, transcends the drug discovery, development, regulation, and utilization continuum to catalyze, evolve, and disseminate discipline ...
Terzic, Andre, Waldman, Scott A.
core   +2 more sources

Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine

Cell Death and Disease
Venetoclax plus azacitidine treatment is clinically beneficial for elderly and unfit acute myeloid leukemia (AML) patients. However, the treatment is rarely curative, and relapse due to resistant disease eventually emerges.
Mahesh Tambe, Sarah Unterberger, Mette C. Kriegbaum, Ida Vänttinen, Ezgi June Olgac, Markus Vähä-Koskela, Mika Kontro, Krister Wennerberg, Caroline A. Heckman   +8 more
doaj   +1 more source

Zebrafish Model of MLL-Rearranged Acute Myeloid Leukemia [PDF]

, 2020
Background: Acute myeloid leukemia (AML) is the second most common type of leukemia. Standard treatment includes chemotherapy as well as stem cell transplantation, but for aging patients and those with impaired immune function these rigorous therapies ...
Belt, Alex, Corey, Seth J., Grant, Steven, Rothschild, Sarah C., Tombes, Robert M.   +4 more
core   +1 more source

Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. [PDF]

, 2015
TCF3-HLF-positive acute lymphoblastic leukemia (ALL) is currently incurable. Using an integrated approach, we uncovered distinct mutation, gene expression and drug response profiles in TCF3-HLF-positive and treatment-responsive TCF3-PBX1-positive ALL. We
Amstislavskiy, V., Badarinarayan, N., Bartram, T., Baruchel, A., Basso, G., Borkhardt, A., Bornhauser, B., Bourquin, J.P., Canpolat, C., Cario, G., Cavé, H., Dakaj, D., Delorenzi, M., Dobay, M.P., Eckert, C., Ellinghaus, E., Eugster, S., Fischer, U., Forster, M., Franke, A., Frismantas, V., Ginzel, S., Gombert, M., Haas, O.A., Heidenreich, O., Hemmrich-Stanisak, G., Hezaveh, K., Hornhardt, S., Husemann, P., Höll, J.I., Kachroo, P., Korbel, J.O., Kratsch, C., Kratz, C.P., Kronnie, G.T., Lehrach, H., Marovca, B., McHardy, A.C., Moorman, A.V., Niggli, F., Panzer-Grümayer, R., Petersen, B.S., Raeder, B., Ralser, M., Rinaldi, A., Risch, T., Rosenstiel, P., Schrappe, M., Schreiber, S., Schäfer, D., Schütte, M., Stade, B., Stanulla, M., Stütz, A.M., Sultan, M., Sungalee, S., Tchinda, J., Thiele, R., Vora, A., Warnatz, H.J., Weid, N.v., Worth, C.L., Yaspo, M.L., Zaliova, M., Zhang, L., Zichner, T., Zimmermann, M.   +66 more
core   +1 more source

Cell wall target fragment discovery using a low‐cost, minimal fragment library

FEBS Letters, EarlyView.
LoCoFrag100 is a fragment library made up of 100 different compounds. Similarity between the fragments is minimized and 10 different fragments are mixed into a single cocktail, which is soaked to protein crystals. These crystals are analysed by X‐ray crystallography, revealing the binding modes of the bound fragment ligands.
Kaizhou Yan, Mathew Stanley, Olawale Raimi, Andrew T. Ferenbach, Helge C Dorfmueller, Daan M. F. van Aalten   +5 more
wiley   +1 more source

Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor

Clinical and Translational Science
Venetoclax, a highly potent BCL‐2 inhibitor, is indicated for treatment of some hematologic malignancies as monotherapy, and/or in combination with other agents.
Ahmed Hamed Salem, Rajeev M. Menon
doaj   +1 more source